Olaparib Maintenance With Pembrolizumab & Bevacizumab in BRCA Non-mutated Patients With Platinum-sensitive Recurrent Ovarian Cancer

Phase 2 Enrolling by invitation 44 enrolled Yonsei University

NaSingle-groupOpen-labelTreatment

Summary

This study is phase II, open label, clinical trial to determine the efficacy of Olaparib maintenance with Bevacizumab and Pembrolizumab by assessment progression-free survival(6 months PFS rate) in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer.

Timeline

Start: 2020-10-28
Primary completion: 2026-05
Completion: 2026-08

Publications

Lee YJ, Lim MC, Kim BG, Ngoi NY, Choi CH, Park SY, Tan DS, Go Y, Lee JY. A single-arm phase II study of olaparib maintenance with pembrolizumab and bevacizumab in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer (OPEB-01). J Gynecol Oncol. 2021 Mar;32(2):e31. doi: 10.3802/jgo.2021.32.e31. Epub 2021 Jan 27.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bevacizumab	Monoclonal antibody	7.5 mg/kg	—
Subject	Bevacizumab	Monoclonal antibody	15 mg/kg	—
Subject	Olaparib	Small molecule	300 mg	—
Subject	Pembrolizumab	Monoclonal antibody	200 mg	—

Indications

No indication recorded.